Human interleukin 2-polyethylene glycol conjugate and application thereof

A technology of interleukin and polyethylene glycol, which is applied in the field of human interleukin 2-polyethylene glycol conjugates, can solve the problems of weakened binding ability, complicated mechanism of action, and no performance, so as to reduce the binding activity , high product uniformity, and the effect of reducing the frequency of administration

Active Publication Date: 2021-12-14
NOVOCODEX BIOPHARMACEUTICALS CO LTD
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] 1. Simple amino acid site-directed mutation can reduce the binding ability to IL-2Rα, or enhance the binding ability to IL-2Rβ or IL-2Rγ, but it cannot effectively prolong the half-life of the molecule, and the mutant product is prone to immunogenic reactions in vivo , it is easy to reduce the biological activity of the product and cause a greater risk of toxicity
[0008] 2. Although simple fusion expression (such as fusion with Fc or HSA) or IL-2 modification can prolong the half-life of the molecule, it has no obvious advantage in actual use compared with unmodified IL-2
Fusion expression can only realize the modification of the fusion molecule at the N-terminus or C-terminus of the target protein, and cannot optimize the modification site
[0009] 3. Partial site-directed mutation combined with fusion expression of IL-2 does not show special advantages in practical application
[0010] 4. Conventional non-site-specific coupling of PEGylated IL-2 does not show special advantages in practical applications. PEGylated IL-2 that comprehensively weakens the binding ability of IL-2Rα has achieved staged success, but the non-site-specific coupling process The characteristics make it difficult to control the production process and quality, the molecular structure is complicated, and the mechanism of action is complicated.
However, this coupling method and chemical modification method need to introduce a relatively expensive alkyne structure, and an acceptable drug-antibody coupling ratio can only be obtained when the equivalent is used, which increases the corresponding production cost and process. The process is also more complex and the process conditions are harsh

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human interleukin 2-polyethylene glycol conjugate and application thereof
  • Human interleukin 2-polyethylene glycol conjugate and application thereof
  • Human interleukin 2-polyethylene glycol conjugate and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0078] The reagents or raw materials used in the preparation examples and examples of the present invention are all commercially available products unless otherwise specified; the experimental methods used are all conventional methods in the art unless otherwise specified.

[0079] Human YT cells in the literature "Yodoi, J. et al. (1985). TCGF(IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YTcells). Journal of Immunology, 134(3), 1623-1630", the public can obtain from Zhejiang Xinma Biomedical Co., Ltd.

preparation example 1

[0080] Preparation Example 1 The preparation of unnatural amino acid NOBK

[0081] The structural formula of NOBK is as follows:

[0082]

[0083] The reaction process is as follows:

[0084]

[0085] The preparation process includes the following steps:

[0086] a) In the reaction flask, add 3-buten-1-ol (2.00g, 27.74mmol), add solvent DCM (15.0mL), add CDI (4.50g, 27.74mmol) at 0C °, the mixture is at room temperature After reacting for 18 hours, 10 mL of water was added, extracted three times with DCM, the organic phases were combined, dried by adding anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain product 1-1 (4.50 g, yield 98%).

[0087] b) In a reaction flask, add product 1-1 (0.55g, 3.31mmol) and Fmoc-lysine hydrochloride (1.12g, 2.76 mmol), add solvent dioxane 9mL and water 3mL (v / v =3:1), then added triethylamine (0.70g, 6.9mmol), and reacted the mixture at room temperature for 24 hours, then added 20mL of 1M HCl solution...

preparation example 2

[0091] Preparation Example 2 The preparation of unnatural amino acid NOHK

[0092] The structural formula of NOHK ​​is as follows:

[0093]

[0094] The reaction process is as follows:

[0095]

[0096] The preparation process includes the following steps:

[0097] a) In a reaction flask, add 5-oxohexanoic acid (2.60g, 20.0mmol), N-hydroxysuccinimide (2.30g, 20.0mmol), EDCI (3.83g, 20.0mmol), add solvent DCM (100 mL), the mixture was reacted at room temperature for 18 hours, washed with water three times, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain product 2-1 (4.62 g, yield 102%), which was directly used in the next step without purification.

[0098] b) In a reaction flask, add product 2-1 (4.62g, 20.35mmol) and Boc-lysine (4.42g, 16.96mmol), then add DIPEA (4.07mL, 42.4mmol), add solvent DMF (50mL) , the mixture was reacted at 40°C for 24 hours, washed with water 5 times, dried by adding anhydrous sodium sulfate, filtered,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a human interleukin 2-polyethylene glycol conjugate and application thereof. The human interleukin 2-polyethylene glycol conjugate provided by the invention comprises recombinant human interleukin 2 containing at least one non-natural amino acid and PEG coupled to the at least one non-natural amino acid, the non-natural amino acid is a carbonyl terminal group-containing compound with a structure as shown in a formula (I) or an enantiomer thereof, and PEG is coupled to the at least one non-natural amino acid by forming an oxime bond between the carbonyl end group and PEG containing a hydroxylamine end group. The human interleukin 2-polyethylene glycol conjugate provided by the invention can be singly used or combined with other anti-tumor drugs, and is used for treating diseases such as solid tumors and hematologic tumors.

Description

technical field [0001] The invention relates to the field of biopharmaceuticals, in particular to a human interleukin 2-polyethylene glycol conjugate and an application thereof. Background technique [0002] Interleukin-2 (Interleukin 2, IL-2, often referred to as Interleukin 2) is an important immune regulatory factor produced by activated type I helper T lymphocytes (Th1), once known as T cell growth factor, Its main biological function is to promote T cells (including CD4 + and CD8 + T cells) growth, proliferation, differentiation, and promote the further secretion of cytokines. In addition, interleukin 2 also stimulates the proliferation of NK cells, enhances NK killing activity and produces cytokines, induces the production of LAK cells; promotes the proliferation of B cells and secretes antibodies; Important role (Gaffena S.L., Cytokine 28:109e123, 2004). [0003] Since the first discovery of IL-2 by Morgan et al. in 1976, it has been widely used clinically. In 19...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/55A61K38/20A61K47/60A61P37/04A61P35/00A61P35/02
CPCC07K14/55A61K47/60A61P37/04A61P35/00A61P35/02A61K38/00Y02A50/30
Inventor 梁学军叶诚浩夏钢陈龙飞霍鹏超杨金纬应跃斌宫丽颖林欣巩尊洋衡新朱小愚朱丽飞黄浩叶谋田丁文焦琳祝静静
Owner NOVOCODEX BIOPHARMACEUTICALS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap